George Dickson

Egham Hill, Surrey
Egham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.

Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 28, 2025

Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression.

Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression.

Journal: Biomedicines

Published: June 10, 2022

Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.

Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.

Journal: Human gene therapy

Published: January 26, 2022

Gene Therapy for Duchenne Muscular Dystrophy.

Gene Therapy for Duchenne Muscular Dystrophy.

Journal: Journal of neuromuscular diseases

Published: September 13, 2021

Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I.

Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I.

Journal: Molecular therapy. Nucleic acids

Published: July 28, 2021

Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice.

Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice.

Journal: Nucleic acid therapeutics

Published: June 03, 2021

Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMDmdx rat model.

Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMDmdx rat model.

Journal: Gene therapy

Published: April 12, 2021

Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element.

Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element.

Journal: Human gene therapy

Published: March 26, 2021

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Journal: Human molecular genetics

Published: March 09, 2021

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy.

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy.

Journal: Molecular therapy. Nucleic acids

Published: July 02, 2020

Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Mutation-Directed Therapeutics for Neurofibromatosis Type I.

Journal: Molecular therapy. Nucleic acids

Published: February 06, 2020

Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease.

Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease.

Journal: Frontiers in physiology

Published: December 19, 2019

Showing 1-12 of 69

Last Updated: 09/26/2026